|
|
1545 Sawtelle Blvd., Suite 36
Los Angeles, CA 90025 USA
phone:(310) 914-0091
fax:(310) 914-0095
|
|
| Symbol |
Private |
| Founded |
2001 |
| Employees |
7 |
|
|
| www.lernermedical.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| UV Phototherapy for home treatment of Psoriasis and other Photoresponsive Skin Conditions |
|
| Management |
| Ethan Lerner, M.D., Ph.D., Chairman; John R. Lyon, BA, President and CEO; Zafiris Gourgouliatos, Ph.D., Chief Technology Officer, and a Company co-founder; David Chang, BSME, Vice President |
| |
|
|
| |
|
| Keywords |
| phototherapy, UV, psoriasis, dermatology |
|
|
|
| Description |
|
Lerner Medical Devices, Inc. uses its proprietary UV phototherapy technology to develop, manufacture and market medical devices for the home treatment of skin conditions and diseases. |
|
| Products / Services |
The company's portfolio includes the Levia Home-Use PhotoTherapy System for the phototherapeutic treatment of scalp and small-area psoriasis. The company aims to become a market and technology leader in developing and supplying high-intensity, targeted phototherapy devices for the treatment of psoriasis and other photoresponsive skin diseases (including eczema, seborrheic dermatitis and vitiligo). The potential benefits of the company's phototherapy systems include: less expensive and time-consuming treatment options for psoriasis patients, as well as the lack of detrimental side effects associated with prolonged steroid use or major organ toxicity hazards associated with systemic and/or biological treatment options.
|
|
| Technology / Differentiation |
| Lerner Medical utilizes advanced HIFOL (High Intensity Fiber Optic Light) optical technology to provide phototherapeutic approaches to treatment of skin conditions. Employing a patented quartz fiber-optic UV light delivery mechanism, the Levia Targeted PhotoTherapy System delivers concentrated and targeted doses of ultraviolet light (UVB) to psoriasis-affected skin at a therapeutic intensity only previously available in physician office systems. |
|
| Market / Customers |
Over six million people in the United States suffer from psoriasis, a chronic inflammatory condition characterized by red scaly patches on the skin that may be associated with itchiness, pain, and bleeding. About 80% of these individuals have a mild or moderate skin disease for which the company's products are indicated. More than $5 billion is spent annually on prescription drugs and physician services in the United States to treat psoriasis. According to a survey from the National Psoriasis Foundation (2002), many psoriasis patients were unsatisfied with treatment and often ceased their therapy. Patients, physicians and third-party payers are actively looking for a better way to treat psoriasis.
|
|
| Funding |
| To date, Lerner Medical Devices, Inc. has financed its operations with an initial angel-financing round of $1.3 million augmented by $0.8 million in SBIR research grants to support product development and efficacy studies. This initial funding has been followed by the company's start-up financing round of $3.3 million closing in December 2007. |
|
| Status |
| The Company expects to begin marketing of the Levia Home-Use Phototherapy System in Q42009. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members